Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF

Recruiting now · Phase 1

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Idiopathic pulmonary fibrosis

Key facts

Study ID

NCT05016817

Run by

The Foundation for Orthopaedics and Regenerative Medicine

People needed

20

Starts

2022-07-03

Expected to finish

2025-11-01

Last updated by the study team

2025-04-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Idiopathic Pulmonary Fibrosis
• Understanding and willingness to sign a written informed consent document

You may not qualify if…

• Active infection
• Active cancer
• Chronic multisystem organ failure
• Pregnancy
• Clinically significant Abnormalities on pre-treatment laboratory evaluation
• Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
• Continued drug abuse
• Pre-menopausal women not using contraception
• Previous organ transplant
• Hypersensitivity to sulfur

Where it is running

• Medical Surgical Associates Center — St John's, Antigua and Barbuda (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.